- |||||||||| JNJ-69086420 / J&J
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (Available On Demand; 281a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3712; P1 Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of 10 Feb 2022, 4 sites have been initiated and 23 patients enrolled; currently, dose escalation is ongoing.
- |||||||||| JNJ-69086420 / J&J
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (In-Person & On Demand | Level 1, West Hall - Q6) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_226; P1 Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of Sep 2021, 4 sites have been initiated and 14 pts enrolled; currently, dose escalation is ongoing.
|